JP2008546687A5 - - Google Patents

Download PDF

Info

Publication number
JP2008546687A5
JP2008546687A5 JP2008516813A JP2008516813A JP2008546687A5 JP 2008546687 A5 JP2008546687 A5 JP 2008546687A5 JP 2008516813 A JP2008516813 A JP 2008516813A JP 2008516813 A JP2008516813 A JP 2008516813A JP 2008546687 A5 JP2008546687 A5 JP 2008546687A5
Authority
JP
Japan
Prior art keywords
tumor
antigen
protein
immunotherapeutic
tuaa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008516813A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008546687A (ja
Filing date
Publication date
Priority claimed from US11/155,288 external-priority patent/US20060008468A1/en
Application filed filed Critical
Publication of JP2008546687A publication Critical patent/JP2008546687A/ja
Publication of JP2008546687A5 publication Critical patent/JP2008546687A5/ja
Pending legal-status Critical Current

Links

JP2008516813A 2005-06-17 2005-12-29 種々の型の癌の診断における腫瘍関連抗原の組合せ Pending JP2008546687A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/155,288 US20060008468A1 (en) 2004-06-17 2005-06-17 Combinations of tumor-associated antigens in diagnostics for various types of cancers
PCT/US2005/047443 WO2007001476A1 (en) 2005-06-17 2005-12-29 Combinations of tumor-associated antigens in diagnostics for various types of cancer

Publications (2)

Publication Number Publication Date
JP2008546687A JP2008546687A (ja) 2008-12-25
JP2008546687A5 true JP2008546687A5 (https=) 2009-02-26

Family

ID=36636429

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008516813A Pending JP2008546687A (ja) 2005-06-17 2005-12-29 種々の型の癌の診断における腫瘍関連抗原の組合せ

Country Status (6)

Country Link
US (2) US20060008468A1 (https=)
EP (1) EP1896854A1 (https=)
JP (1) JP2008546687A (https=)
CA (1) CA2612512A1 (https=)
MX (1) MX2007015946A (https=)
WO (1) WO2007001476A1 (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6977074B2 (en) 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
CA2360073C (en) * 1999-01-28 2011-01-18 Gen-Probe Incorporated Probes and primers for detecting prostate specific antigen (psa) in a biological sample
US7178491B2 (en) * 2003-06-05 2007-02-20 Caterpillar Inc Control system and method for engine valve actuator
US20060159689A1 (en) * 2004-06-17 2006-07-20 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
US8202841B2 (en) * 2004-06-17 2012-06-19 Mannkind Corporation SSX-2 peptide analogs
EP1773402A2 (en) * 2004-06-17 2007-04-18 Mannkind Corporation Improved efficacy of immunotherapy by integrating diagnostic with therapeutic methods
EP1838338A2 (en) 2004-12-29 2007-10-03 Mannkind Corporation Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs
EP1838342A2 (en) * 2004-12-29 2007-10-03 Mannkind Corporation Methods to bypass cd+4 cells in the induction of an immune response
AU2005321898B2 (en) * 2004-12-29 2012-07-19 Mannkind Corporation Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines
US20060165711A1 (en) * 2004-12-29 2006-07-27 Bot Adrian I Methods to elicit, enhance and sustain immune responses against MHC class I-restricted epitopes, for prophylactic or therapeutic purposes
NZ564359A (en) * 2005-06-17 2011-09-30 Mannkind Corp Analogs of pepetides corresponding to class I MHC-restricted T cell epitopes
CN101687020A (zh) 2005-06-17 2010-03-31 曼康公司 用于癌症的多价引发-和-增强免疫治疗剂
MX2007015933A (es) 2005-06-17 2008-04-21 Mannkind Corp Metodos y composiciones para generar respuestas inmunes multivalentes contra espitopes dominantes y subdominantes, expresados en celulas cancerigenas y estromas tumorales.
WO2007109321A2 (en) 2006-03-20 2007-09-27 The Regents Of The University Of California Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
WO2008008541A2 (en) * 2006-07-14 2008-01-17 Mannkind Corporation Methods to elicit, enhance and sustain immune responses against mhc class-i restricted epitopes, for prophylactic or therapeutic purposes
WO2008039974A2 (en) 2006-09-28 2008-04-03 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
US8940298B2 (en) 2007-09-04 2015-01-27 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection
WO2009068621A1 (en) * 2007-11-30 2009-06-04 Glaxosmithkline Biologicals S.A. Method for classifying cancer patients as responder or non-responder to immunotherapy
WO2009127046A1 (en) * 2008-04-14 2009-10-22 Proscan Rx Pharma Inc. Prostate specific membrane antigen antibodies and antigen binding fragments
US9101537B2 (en) 2008-07-25 2015-08-11 Reven Pharmaceuticals, Inc. Compositions and methods for the prevention and treatment of cardiovascular diseases
AU2010310468A1 (en) 2009-10-23 2012-05-24 Mannkind Corporation Cancer immunotherapy and method of treatment
BR112012029066A2 (pt) * 2010-05-14 2020-09-01 The General Hospital Corporation composições e processos de identificação de neoantígenos específicos de tumor.
RU2537263C2 (ru) * 2012-10-22 2014-12-27 Федеральное Государственное Бюджетное Образовательное Учреждение Высшего Профессионального Образования "Нижегородский Государственный Университет Им. Н.И. Лобачевского" Способ скрининга и мониторинга онкологических заболеваний и набор для его осуществления (варианты)
EP2956164A4 (en) * 2013-02-14 2016-08-31 Immunocellular Therapeutics Ltd Ovarian cancer vaccines and vaccination methods
US10137182B2 (en) 2013-02-14 2018-11-27 Immunocellular Therapeutics, Ltd. Cancer vaccines and vaccination methods
WO2014187881A1 (en) * 2013-05-21 2014-11-27 Max-Planck Gesellschaft zur Förderung der Wissenschaften e.V. Isoforms of gata6 and nkx2-1 as markers for diagnosis and therapy of cancer and as targets for anti-cancer therapy
WO2015070045A1 (en) 2013-11-08 2015-05-14 Baylor College Of Medicine A novel diagnostic/prognostic markers and therapeutic target for cancer
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
EP3082853A2 (en) 2013-12-20 2016-10-26 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
US10993997B2 (en) * 2014-12-19 2021-05-04 The Broad Institute, Inc. Methods for profiling the t cell repertoire
TW202523682A (zh) 2015-05-20 2025-06-16 美商博德研究所有限公司 共有之gata3相關之腫瘤特異性新抗原
GB201607535D0 (en) * 2016-04-29 2016-06-15 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520568D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd Peptides
GB201520550D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
WO2017176946A1 (en) * 2016-04-05 2017-10-12 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for targeted therapy based on single-cell stimulus perturbation response
CA3056212A1 (en) 2016-04-07 2017-10-12 Bostongene Corporation Construction and methods of use of a therapeutic cancer vaccine library comprising fusion-specific vaccines
WO2018140391A1 (en) 2017-01-24 2018-08-02 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
JP7216995B2 (ja) * 2018-12-05 2023-02-02 学校法人関西医科大学 胸腺癌バイオマーカー及び胸腺腫瘍の予後予測マーカー
US12531162B1 (en) * 2023-05-31 2026-01-20 Northeastern University Multi-dimensional phenotypic space for genotype to phenotype mapping and intelligent design of cancer drug therapies using a deep learning net
US12562256B2 (en) * 2023-11-07 2026-02-24 New York University Systems, methods and computer-accessible medium for identifying target pairs for CAR-T therapy

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4940670A (en) * 1986-01-24 1990-07-10 Rhodes Buck A Method for compounding and testing patient specific monoclonal antibodies and monoclonal antibody fragments for in vivo use
US5804381A (en) * 1996-10-03 1998-09-08 Cornell Research Foundation Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
ES2276390T3 (es) * 1992-11-05 2007-06-16 Sloan-Kettering Institute For Cancer Research Antigeno de membrana especifico de la prostata.
US5747271A (en) * 1992-12-22 1998-05-05 Ludwig Institute For Cancer Research Method for identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of HLA-A2/tyrosinase derived peptides, and methods for treating said individuals
US5620886A (en) * 1993-03-18 1997-04-15 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
US5571711A (en) * 1993-06-17 1996-11-05 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for BAGE tumor rejection antigen precursors
US5610013A (en) * 1993-07-22 1997-03-11 Ludwig Institute For Cancer Research Method for diagnosing a disorder by determining expression of gage tumor rejection antigen precursors
US6013481A (en) * 1993-07-22 2000-01-11 Ludwig Institute For Cancer Research Isolated, nucleic acid molecules which code for gage tumor rejection antigen, the tumor rejection antigen, and uses thereof
US5858689A (en) * 1993-07-22 1999-01-12 Ludwig Institute For Cancer Research Isolated peptides derived from the gage tumor rejection antigen precursor and uses thereof
US5648226A (en) * 1993-07-22 1997-07-15 Ludwig Institute For Cancer Research Isolated peptides derived from tumor rejection antigens, and their use
US5679647A (en) * 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5935818A (en) * 1995-02-24 1999-08-10 Sloan-Kettering Institute For Cancer Research Isolated nucleic acid molecule encoding alternatively spliced prostate-specific membrane antigen and uses thereof
US5874560A (en) * 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
US5830753A (en) * 1994-09-30 1998-11-03 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.
US6025191A (en) * 1995-06-07 2000-02-15 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which encode a melanoma specific antigen and uses thereof
US5856136A (en) * 1996-07-03 1999-01-05 Incyte Pharmaceuticals, Inc. Human stem cell antigens
US6994851B1 (en) * 1997-07-10 2006-02-07 Mannkind Corporation Method of inducing a CTL response
US6977074B2 (en) * 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US6709844B1 (en) * 2000-11-16 2004-03-23 Mannkind Corporation Avoidance of undesirable replication intermediates in plasmid propagation
US20030138808A1 (en) * 1998-02-19 2003-07-24 Simard John J.L. Expression vectors encoding epitopes of target-associated antigens
EP1179541B1 (en) * 1999-04-28 2004-06-16 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting VEGF
JP3911905B2 (ja) * 1999-04-30 2007-05-09 松下電工株式会社 インパクト回転工具
US20030215425A1 (en) * 2001-12-07 2003-11-20 Simard John J. L. Epitope synchronization in antigen presenting cells
US6861234B1 (en) * 2000-04-28 2005-03-01 Mannkind Corporation Method of epitope discovery
WO2002007783A2 (en) * 2000-07-20 2002-01-31 Regents Of The University Of Minnesota Radiolabeled immunotoxins
JP2005505242A (ja) * 2001-03-07 2005-02-24 マンカインド コーポレイション 癌用抗新生血管系調製物
WO2003008537A2 (en) * 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
US8637305B2 (en) * 2001-11-07 2014-01-28 Mannkind Corporation Expression vectors encoding epitopes of target-associated antigens and methods for their design
US20040063120A1 (en) * 2002-07-10 2004-04-01 The Regents Of The University Of Michigan Expression profile of lung cancer
WO2004022709A2 (en) * 2002-09-06 2004-03-18 Mannkind Corporation Epitope sequences
DE602004028468D1 (de) * 2003-06-17 2010-09-16 Mannkind Corp Haltung von immunantworten gegen mhc-klasse-i-beschränkte epitope, für prophylaktische oder therapeutische zwecke
AU2004249254B2 (en) * 2003-06-17 2010-07-08 Mannkind Corporation Combinations of tumor-associated antigens for the treatment of various types of cancers
WO2005054508A2 (en) * 2003-12-01 2005-06-16 Ipsogen Gene expression profiling of colon cancer by dna microarrays and correlation with survival and histoclinical parameters
EP1773402A2 (en) * 2004-06-17 2007-04-18 Mannkind Corporation Improved efficacy of immunotherapy by integrating diagnostic with therapeutic methods
JP2008503498A (ja) * 2004-06-17 2008-02-07 マンカインド コーポレイション 癌の診断及び免疫療法における腫瘍関連抗原プロファイル
US8202841B2 (en) * 2004-06-17 2012-06-19 Mannkind Corporation SSX-2 peptide analogs

Similar Documents

Publication Publication Date Title
JP2008546687A5 (https=)
JP2008503498A5 (https=)
Esfandiary et al. MAGE-A3: an immunogenic target used in clinical practice
Yamada et al. Next‐generation peptide vaccines for advanced cancer
Sarivalasis et al. A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma
Madan et al. Clinical evaluation of TRICOM vector therapeutic cancer vaccines
Hirayama et al. The present status and future prospects of peptide-based cancer vaccines
Cloosen et al. Expression of tumor-associated differentiation antigens, MUC1 glycoforms and CEA, in human thymic epithelial cells: implications for self-tolerance and tumor therapy
Imai et al. Identification of a novel tumor-associated antigen, cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancers
Wu et al. PSCA is a target of chimeric antigen receptor T cells in gastric cancer
Ishikawa et al. Phase I clinical trial of vaccination with LY6K-derived peptide in patients with advanced gastric cancer
Lee et al. Expression of NY-ESO-1 in triple-negative breast cancer is associated with tumor-infiltrating lymphocytes and a good prognosis
Funt et al. The role of neoadjuvant trials in drug development for solid tumors
Thor Straten et al. Targetless T cells in cancer immunotherapy
De Pas et al. Vaccines in non-small cell lung cancer: rationale, combination strategies and update on clinical trials
McCarthy et al. AE37: a HER2-targeted vaccine for the prevention of breast cancer recurrence
Faramarzi et al. Melanoma: a prototype of cancer-testis antigen-expressing malignancies
Hale et al. Cancer vaccines: should we be targeting patients with less aggressive disease?
Schneble et al. Peptide-based cancer vaccine strategies and clinical results
Page et al. Emerging immunotherapy strategies in breast cancer
Jafferji et al. Adoptive T-cell therapy for solid malignancies
Dumbrava et al. Abstract OT-03-02: Phase 1/2 study of a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), BDC-1001, as a single agent and in combination with an immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors
De La Cruz et al. Restoring anti-oncodriver Th1 responses with dendritic cell vaccines in HER2/neu-positive breast cancer: progress and potential
Tsukahara et al. Peptide vaccination therapy: towards the next generation
Schlom et al. Paradigm shifts in cancer vaccine therapy